Adverum Biotechnologies, Inc. Sale Investigation
Investor rights law firm Halper Sadeh LLC is currently conducting an investigation into the proposed sale of Adverum Biotechnologies, Inc. (NASDAQ: ADVM) to Eli Lilly and Company. The exploration is focused on whether the terms of this sale are truly fair to the shareholders of Adverum.
Understanding the Terms of the Sale
As per the outlined terms of the proposed deal, shareholders of Adverum are expected to receive $3.56 in cash for each share held, along with one non-transferrable contingent value right (CVR). This CVR is significant as it potentially entitles the holder to an additional $8.91 in cash, contingent upon the fulfillment of specific company milestones.
Evaluating Shareholder Rights
Halper Sadeh LLC is encouraging shareholders of Adverum to be proactive in understanding their rights and options regarding this merger. They emphasize the importance of being informed and equipped to navigate these proceedings effectively.
Legal Representation for Investors
The firm may seek enhanced compensation for investors, along with necessary disclosures that are essential for shareholders to assess the deal's fairness accurately. Notably, the legal action will be handled on a contingent fee basis, implying that shareholders are not responsible for any upfront legal costs or expenses.
Insights into Corporate Governance
The investigation raises significant inquiries about whether Adverum's board of directors acted in the best interest of its shareholders. Key points of concern include whether they secured the best possible offer for shareholders, their assessment of Eli Lilly's proposed payment, and the complete disclosure of material facts relating to the merger.
Halper Sadeh's Commitment to Shareholders
Halper Sadeh LLC has a long-standing history of advocating for investor rights globally. They have effectively championed causes concerning corporate misconduct, helping to implement reforms and retrieve substantial financial recoveries for affected investors.
Contacting Halper Sadeh LLC
Potential clients or interested shareholders can reach out for more direct inquiries. Halper Sadeh LLC can be contacted at (212) 763-0060, or through the emails provided for Daniel Sadeh and Zachary Halper.
Frequently Asked Questions
What is the current status of the Adverum sale?
The investigation by Halper Sadeh LLC is ongoing, analyzing the fairness of the terms offered to shareholders in the sale to Eli Lilly.
How can Adverum shareholders participate in the investigation?
Shareholders are encouraged to reach out to Halper Sadeh LLC to learn about their options and rights concerning the sale.
Will there be any cost involved for shareholders?
No, the legal representation by Halper Sadeh LLC is on a contingent fee basis, meaning no upfront costs are required from shareholders.
What specific aspects are being investigated?
The investigation is looking into whether the board of Adverum acted against shareholder interests by possibly underestimating the value of their shares in the sale to Eli Lilly.
How successful has Halper Sadeh LLC been in similar cases?
Halper Sadeh LLC has a strong track record of recovering funds for investors and advocating for corporate reform, ensuring their rights are upheld.
